

Glenmark

GLENMARK PHARMACEUTICALS LIMITED

Registered Office: B/2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, Mumbai - 400 026;
 Corporate Office: Glenmark House, B. D. Sawant Marg, Chakala, Off. Western Express Highway, Andheri (E), Mumbai - 400099.
 Phone No: +91 22 4018 9999 Fax No.: +91 22 4018 9986 Website: www.glenmarkpharma.com; Email: complianceofficer@glenmarkpharma.com
 CIN: L24299MH1977PLC019982

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30 SEPTEMBER, 2024

(All amounts in million of Indian Rupees, unless otherwise stated)

Sr. No.	Particulars	Standalone						Consolidated					
		Quarter ended	Quarter ended	Quarter ended	Half year ended	Half year ended	Year ended	Quarter ended	Quarter ended	Quarter ended	Half year ended	Half year ended	Year ended
		30/09/2024	30/06/2024	30/09/2023	30/09/2024	30/09/2023	31/03/2024	30/09/2024	30/06/2024	30/09/2023	30/09/2024	30/09/2023	31/03/2024
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	
I	Revenue from operations												
	(a) Net sales	25,948.91	22,968.75	21,704.03	48,917.66	42,684.65	76,497.61	34,004.98	32,233.02	31,606.87	66,238.00	61,591.59	1,16,354.56
	(b) Other operating income	412.08	326.62	630.13	738.70	1,093.35	2,413.58	332.98	208.84	466.91	541.82	842.85	1,776.41
	Total revenue from operations	26,360.99	23,295.37	22,334.16	49,656.36	43,778.00	78,911.19	34,337.96	32,441.86	32,073.78	66,779.82	62,434.44	1,18,130.97
II	Other income	830.77	556.48	735.78	1,387.25	1,229.39	11,680.24	394.17	314.92	16.97	709.09	214.19	8,399.94
III	Total income (I + II)	27,191.76	23,851.85	23,069.94	51,043.61	45,007.39	90,591.43	34,732.13	32,756.78	32,090.75	67,488.91	62,648.63	1,26,530.91
IV	Expenses												
	(a) Cost of materials consumed	7,225.66	6,481.09	8,070.30	13,706.75	16,037.85	29,904.11	7,743.57	6,857.74	9,157.53	14,601.31	17,460.07	31,578.22
	(b) Purchases of stock-in-trade	1,036.52	889.85	812.30	1,926.37	1,634.01	3,227.82	4,088.34	3,600.26	4,088.34	8,031.09	8,272.59	14,511.70
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	78.84	569.24	60.76	648.08	(170.08)	(1,030.70)	(1,473.63)	642.82	(1,268.03)	(830.81)	(1,876.85)	(1,956.22)
	(d) Employee benefits expense	4,084.15	3,844.03	3,830.03	7,928.18	7,174.69	14,347.75	7,865.65	7,104.40	14,970.05	14,141.52	28,681.43	58,603.67
	(e) Finance costs	117.95	153.49	581.87	271.44	1,201.21	2,771.10	484.79	395.82	1,214.58	880.61	2,330.66	5,159.69
	(f) Depreciation, amortisation and impairment expense	548.49	530.87	498.46	1,079.36	985.99	2,021.62	1,414.54	1,177.89	1,214.58	2,380.67	2,330.66	5,819.06
	(g) Other expenses	6,149.56	5,200.14	5,125.87	11,349.70	9,816.66	20,045.58	9,752.42	8,354.51	8,144.30	18,106.93	15,440.74	33,362.53
	Total expenses (IV)	19,241.17	17,668.71	18,979.59	36,909.88	36,680.33	71,287.28	30,006.41	30,080.05	30,080.05	58,139.85	58,603.67	1,17,156.41
V	Profit/(loss) before exceptional items and tax (III - IV)	7,950.59	6,183.14	4,090.35	14,133.73	8,327.06	19,304.15	4,725.72	4,623.34	2,010.70	9,349.06	4,044.96	9,009.55
VI	Exceptional items (gain)/ loss (Refer note 5)	196.69	-	196.69	-	512.98	(50,703.31)	-	-	-	-	3,774.46	-
VII	Profit/(loss) before tax from continuing operations (V - VI)	7,950.59	6,183.14	3,893.66	14,133.73	7,814.08	70,007.46	4,725.72	4,623.34	(1,243.53)	9,349.06	270.50	364.95
VIII	Tax expense:												
	Current tax	1,384.63	1,079.84	92.15	2,464.47	477.80	10,499.92	1,359.10	1,468.82	227.28	2,827.92	794.51	11,155.52
	Deferred tax	615.40	565.99	777.97	1,181.39	1,596.18	7,834.63	(178.23)	(247.86)	332.18	14.88	902.20	7,517.93
IX	Profit/(loss) after tax for the period from continuing operations (VII - VIII)	5,950.56	4,537.31	3,023.54	10,487.87	5,740.10	51,672.91	3,544.85	3,402.38	(1,802.99)	6,947.23	(1,426.21)	(18,308.50)
X	Profit/(loss) for the period from continuing operations attributable to:												
	- Non-controlling interests	-	-	-	-	-	-	-	-	-	-	-	-
	- Owners of the Company	5,950.56	4,537.31	3,023.54	10,487.87	5,740.10	51,672.91	3,544.85	3,402.38	(1,802.99)	6,947.23	(1,426.21)	(18,308.50)
XI	Profit/(loss) before tax from discontinued operations	-	-	-	-	-	-	-	-	-	-	-	-
XII	Tax expense of discontinued operations:												
	Current tax	-	-	-	-	-	-	-	-	-	-	-	-
	Deferred tax	-	-	-	-	-	-	-	-	-	-	-	-
XIII	Profit/(loss) after tax for the period from discontinued operations (XI - XII)	-	-	-	-	-	-	-	-	-	-	-	-
XIV	Profit/(loss) for the period from discontinued operations attributable to:												
	- Non-controlling interests	-	-	-	-	-	-	-	-	-	-	-	-
	- Owners of the Company	-	-	-	-	-	-	-	-	-	-	-	-
XV	Profit/(loss) after tax for the period from continuing and discontinued operations (IX + XIII)	-	-	-	-	-	-	-	-	-	-	-	-
XVI	Profit/(loss) for the period from continuing and discontinued operations attributable to:												
	- Non-controlling interests	-	-	-	-	-	-	-	-	-	-	-	-
	- Owners of the Company	5,950.56	4,537.31	3,023.54	10,487.87	5,740.10	51,672.91	3,544.85	3,402.38	(1,802.99)	6,947.23	(1,426.21)	(18,308.50)
XVII	Other comprehensive income from continuing operations												
	A (i) Items that will not be reclassified to profit or loss	(32.59)	(12.52)	(65.31)	(45.11)	(72.81)	(73.14)	(45.41)	(7.01)	(72.46)	(52.42)	(77.98)	(163.06)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	11.39	4.37	29.85	15.76	32.08	25.56	13.74	2.79	29.85	16.53	32.08	42.75
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-	(163.25)	60.50	(762.17)	(102.75)	(1,326.54)	(399.03)
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-	(29.10)	(1.36)	(75.48)	(30.46)	(68.68)	(79.97)
XVIII	Total comprehensive income from continuing operations for the period/ year	5,929.36	4,529.16	2,988.08	10,458.52	5,699.37	51,625.33	3,320.83	3,457.30	(2,683.25)	6,778.13	(2,867.33)	(18,907.81)
XIX	Other comprehensive income from discontinued operations for the period/ year	-	-	-	-	-	-	-	-	(19.89)	-	-	(56.23)
XX	Total comprehensive income from discontinued operations for the period/ year (XIII + XIX)	-	-	-	-	-	-	-	-	(19.89)	-	-	(56.23)
XXI	Other comprehensive income for the period/ year from continuing and discontinued operations (XVIII + XX)	(21.20)	(8.15)	(35.46)	(29.35)	(40.73)	(47.58)	(224.02)	54.92	(900.15)	(169.10)	(1,461.74)	(655.53)
XXII	Total comprehensive income for the period/ year from continuing and discontinued operations (XVIII + XXI)	5,929.36	4,529.16	2,988.08	10,458.52	5,699.37	51,625.33	3,320.83	3,457.30	(1,515.77)	6,778.13	(346.08)	(14,990.76)
XXIII	Total comprehensive income attributable to:												
	- Non-controlling interests	-	-	-	-	-	-	-	-	-	-	-	-
	- Owners of the Company	5,929.36	4,529.16	2,988.08	10,458.52	5,699.37	51,625.33	3,318.39	3,457.56	(1,515.77)	6,778.13	(346.08)	(14,990.76)
XXIV	Paid up Equity Share Capital, Equity Shares of ₹ 1/- each	282.19	282.19	282.17	282.19	282.17	282.19	282.19	282.19	282.17	282.19	282.17	282.19
XXV	Other equity (other than revaluation reserve)	-	-	-	-	-	-	-	-	-	-	-	-
XXVI	Earning per share for continuing operations (EPS) (not annualised except for the year ended 31 March)												
	Basic (in Rupees)	-	-	-	-	-	-	12.55	12.06	(7.11)	24.61	(6.60)	(67.30)
	Diluted (in Rupees)	-	-	-	-	-	-	12.55	12.06	(7.11)	24.61	(6.60)	(67.30)
XXVII	Earning per share for discontinued operations (EPS) (not annualised except for the year ended 31 March)												
	Basic (in Rupees)	-	-	-	-	-	-	-	-	4.21	-	9.01	14.08
	Diluted (in Rupees)	-	-	-	-	-	-	-	-	4.21	-	9.01	14.08
XXVIII	Earning per share for continuing and discontinued operations (EPS) (not annualised except for the year ended 31 March)												
	Basic (in Rupees)	21.09	16.08	10.72	37.17	20.34	183.13	12.55	12.06	(2.90)	24.61	2.41	(53.22)
	Diluted (in Rupees)	21.09	16.08	10.72	37.17	20.34	183.12	12.55	12.06	(2.90)	24.61	2.41	(53.22)

Glenmark Pharmaceuticals Limited
 Statement of assets and liabilities
 (All amounts in million of Indian Rupees, unless otherwise stated)

Particulars	Standalone		Consolidated	
	As at 30/09/2024 Unaudited	As at 31/03/2024 Audited	As at 30/09/2024 Unaudited	As at 31/03/2024 Audited
ASSETS				
Non current assets				
Property, plant and equipment	15,625.40	14,970.05	29,755.96	29,190.77
Capital work-in-progress	1,697.54	1,754.95	3,951.14	4,193.24
Right of Use Asset	452.59	415.73	1,795.08	1,990.76
Goodwill	-	-	702.66	673.59
Other intangible assets	1,952.42	2,176.67	10,840.52	10,246.50
Intangible assets under development	344.27	221.70	1,973.64	2,425.56
Financial assets				
(i) Investments	1,51,831.64	1,29,647.91	446.11	7,896.64
(ii) Loans	37,878.02	75,056.60	-	-
(iii) Other financial assets	436.98	444.59	700.10	698.83
Deferred tax assets (net)	492.84	1,658.47	10,786.88	10,497.22
Other non-current assets	587.22	1,066.56	1,492.31	1,492.31
Total non-current assets	2,11,298.92	2,27,329.20	62,018.65	69,305.42
Current assets				
Inventories	12,687.68	11,426.86	28,402.06	25,130.51
Financial assets				
(i) Investments	32,981.77	24,844.74	28,634.30	18,584.12
(ii) Trade receivables	9,731.48	1,279.64	18,188.96	16,592.70
(iii) Cash and cash equivalents	11.80	11.86	13.48	11.86
(iv) Bank balance other than cash and cash equivalents	1,370.80	1,305.59	2,204.54	1,735.97
Current tax assets	7,151.74	7,946.05	12,891.43	12,235.66
Total current assets	63,935.27	46,814.74	90,334.77	74,280.82
Total assets	2,75,234.19	2,74,143.94	1,52,353.42	1,43,586.24
EQUITY AND LIABILITIES				
Equity				
Equity share capital	282.19	282.19	282.19	282.19
Other equity	2,39,174.04	2,29,424.01	84,174.39	78,197.08
Equity attributable to owners of Glenmark Pharmaceuticals Limited	2,39,456.23	2,29,706.20	84,456.58	78,479.27
Non-controlling interests	-	-	(1.62)	(3.80)
Liabilities				
Financial liabilities				
(i) Borrowings	-	-	-	-
(ii) Lease liabilities	297.75	224.47	1,400.24	1,516.91
(iii) Other financial liabilities	1,275.69	1,319.39	4,643.40	5,388.28
Deferred tax liabilities (net)	-	-	7.90	2.80
Other non-current liabilities	-	-	16.91	



GLENMARK PHARMACEUTICALS LIMITED

Registered Office: B/2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, Mumbai - 400 026;
Corporate Office: Glenmark House, B. D. Sawant Marg, Chakala, Off. Western Express Highway, Andheri (E), Mumbai - 400099.
Phone No: +91 22 4018 9999 Fax No.: +91 22 4018 9986 Website: www.glenmarkpharma.com; Email: complianceofficer@glenmarkpharma.com
CIN: L24299MH1977PLC019982

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30 SEPTEMBER, 2024

(All amounts in million of Indian Rupees, unless otherwise stated)

Sr. No.	Particulars	Standalone						Consolidated					
		Quarter ended	Quarter ended	Quarter ended	Half year ended	Half year ended	Year ended	Quarter ended	Quarter ended	Quarter ended	Half year ended	Half year ended	Year ended
		30/09/2024	30/06/2024	30/09/2023	30/09/2024	30/09/2023	31/03/2024	30/09/2024	30/06/2024	30/09/2023	30/09/2024	30/09/2023	31/03/2024
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	
I	Revenue from operations												
	(a) Net sales	25,948.91	22,968.75	21,704.03	48,917.66	42,684.65	76,497.61	34,004.98	32,233.02	31,606.87	66,238.00	61,591.59	1,16,354.56
	(b) Other operating income	412.08	326.62	630.13	738.70	1,093.35	2,413.58	332.98	208.84	466.91	541.82	842.85	1,776.41
	Total revenue from operations	26,360.99	23,295.37	22,334.16	49,656.36	43,778.00	78,911.19	34,337.96	32,441.86	32,073.78	66,779.82	62,434.44	1,18,130.97
II	Other income	830.77	556.48	735.78	1,387.25	1,229.39	11,680.24	394.17	314.92	16.97	709.09	214.19	8,399.94
III	Total income (I + II)	27,191.76	23,851.85	23,069.94	51,043.61	45,007.39	90,591.43	34,732.13	32,756.78	32,090.75	67,488.91	62,648.63	1,26,530.91
IV	Expenses												
	(a) Cost of materials consumed	7,225.66	6,481.09	8,070.30	13,706.75	16,037.85	29,904.11	7,743.57	6,857.74	9,157.53	14,601.31	17,460.07	31,578.22
	(b) Purchases of stock-in-trade	1,036.52	889.85	812.30	1,926.37	1,634.01	3,227.82	4,408.34	3,600.26	4,031.09	8,031.09	8,272.59	14,511.70
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	78.84	569.24	60.76	648.08	(170.08)	(1,030.70)	(1,473.63)	642.82	(1,268.03)	(830.81)	(1,876.85)	(1,956.22)
	(d) Employee benefits expense	4,084.15	3,844.03	3,830.03	7,928.18	7,174.69	14,347.75	7,865.65	7,104.40	14,970.05	14,141.52	15,411.52	28,681.43
	(e) Finance costs	117.95	153.49	581.87	271.44	1,201.21	2,771.10	484.79	395.82	1,214.58	880.61	2,330.66	5,159.69
	(f) Depreciation, amortisation and impairment expense	548.49	530.87	498.46	1,079.36	985.99	2,021.62	1,202.78	1,414.54	1,177.89	2,380.67	2,834.94	5,819.06
	(g) Other expenses	6,149.56	5,200.14	5,125.87	11,349.70	9,816.66	20,045.58	9,752.42	8,354.51	8,144.30	15,440.74	15,440.74	33,362.53
	Total expenses (IV)	19,241.17	17,668.71	18,979.59	36,909.88	36,680.33	71,287.28	30,006.41	28,133.44	30,080.05	58,139.85	58,603.67	1,17,156.41
V	Profit/(loss) before exceptional items and tax (III - IV)	7,950.59	6,183.14	4,090.35	14,133.73	8,327.06	19,304.15	4,725.72	4,623.34	2,010.70	9,349.06	4,044.96	9,374.50
VI	Exceptional items (gain)/ loss (Refer note 5)	196.69	-	-	-	512.98	(50,703.31)	-	-	3,254.23	-	3,774.46	9,009.55
VII	Profit/(loss) before tax from continuing operations (V - VI)	7,950.59	6,183.14	3,893.66	14,133.73	7,814.08	70,007.46	4,725.72	4,623.34	(1,243.53)	9,349.06	270.50	364.95
VIII	Tax expense :												
	Current tax	1,384.63	1,079.84	92.15	2,464.47	477.80	10,499.92	1,359.10	1,468.82	227.28	2,827.92	794.51	11,155.52
	Deferred tax	615.40	565.99	777.97	1,181.39	1,596.18	7,834.63	(178.23)	(247.86)	332.18	(426.09)	902.20	7,517.93
IX	Profit/(loss) after tax for the period from continuing operations (VII - VIII)	5,950.56	4,537.31	3,023.54	10,487.87	5,740.10	51,672.91	3,544.85	3,402.38	(1,802.99)	6,947.23	(1,426.21)	(18,308.50)
X	Profit/(loss) for the period from continuing operations attributable to:												
	- Non-controlling interests	-	-	-	-	-	-	-	-	2.71	(0.29)	203.83	435.77
	- Owners of the Company	5,950.56	4,537.31	3,023.54	10,487.87	5,740.10	51,672.91	3,542.14	3,402.67	(2,006.82)	6,947.23	(1,426.21)	(18,308.50)
XI	Profit/(loss) before tax from discontinued operations	-	-	-	-	-	-	-	-	-	-	-	-
XII	Tax expense of discontinued operations :												
	Current tax	-	-	-	-	-	-	-	-	-	387.00	-	1,284.32
	Deferred tax	-	-	-	-	-	-	-	-	-	14.88	-	69.32
XIII	Profit/(loss) after tax for the period from discontinued operations (XI - XII)	-	-	-	-	-	-	-	-	-	1,187.37	-	2,541.87
XIV	Profit/(loss) for the period from discontinued operations attributable to:												
	- Non-controlling interests	-	-	-	-	-	-	-	-	-	-	-	-
	- Owners of the Company	-	-	-	-	-	-	-	-	-	-	-	-
XV	Profit/(loss) after tax for the period from continuing and discontinued operations (IX + XIII)	-	-	-	-	-	-	3,544.85	3,402.38	(1,187.37)	6,947.23	2,541.87	3,973.28
XVI	Profit/(loss) for the period from continuing and discontinued operations attributable to:												
	- Non-controlling interests	-	-	-	-	-	-	-	-	-	-	-	-
	- Owners of the Company	5,950.56	4,537.31	3,023.54	10,487.87	5,740.10	51,672.91	3,542.14	3,402.67	(819.45)	6,947.23	1,115.66	(14,335.22)
XVII	Other comprehensive income from continuing operations												
	A (i) Items that will not be reclassified to profit or loss	(32.59)	(12.52)	(65.31)	(45.11)	(72.81)	(73.14)	(45.41)	(7.01)	(72.46)	(52.42)	(77.98)	(163.06)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	11.39	4.37	29.85	15.76	32.08	25.56	13.74	2.79	29.85	16.53	32.08	42.75
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-	(163.25)	60.50	(762.17)	(102.75)	(1,326.54)	(399.03)
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-	(29.10)	(1.36)	(75.48)	(30.46)	(68.68)	(79.97)
XVIII	Total comprehensive income from continuing operations for the period/ year	5,929.36	4,529.16	2,988.08	10,458.52	5,699.37	51,625.33	3,320.83	3,457.30	(2,683.25)	6,778.13	(2,867.33)	(18,907.81)
XIX	Other comprehensive income from discontinued operations for the period/ year	-	-	-	-	-	-	-	-	(19.89)	-	-	(56.23)
XX	Total comprehensive income from discontinued operations for the period/ year (XIII + XIX)	-	-	-	-	-	-	-	-	-	-	-	-
XXI	Other comprehensive income for the period/ year from continuing and discontinued operation (XVII + XX)	(21.20)	(8.15)	(35.46)	(29.35)	(40.73)	(47.58)	(224.02)	54.92	(900.15)	(169.10)	(1,461.74)	(655.53)
XXII	Total comprehensive income for the period/ year from continuing and discontinued operation (XVIII + XX)	5,929.36	4,529.16	2,988.08	10,458.52	5,699.37	51,625.33	3,320.83	3,457.30	(1,515.77)	6,778.13	(346.08)	(14,990.76)
XXIII	Total comprehensive income attributable to:												
	- Non-controlling interests	-	-	-	-	-	-	-	-	2.44	2.18	432.46	672.00
	- Owners of the Company	5,929.36	4,529.16	2,988.08	10,458.52	5,699.37	51,625.33	3,318.39	3,455.16	(1,716.25)	6,775.95	(778.54)	(15,662.76)
XXIV	Paid up Equity Share Capital, Equity Shares of ₹ 1/- each	282.19	282.19	282.17	282.19	282.17	282.19	282.19	282.19	282.17	282.19	282.17	282.19
XXV	Other equity (other than revaluation reserve)	-	-	-	-	-	2,29,424.01	-	-	-	-	-	78,197.08
XXVI	Earning per share for continuing operations (EPS)												
	(not annualised except for the year ended 31 March)												
	Basic (in Rupees)	-	-	-	-	-	-	12.55	12.06	(7.11)	24.61	(6.60)	(67.30)
	Diluted (in Rupees)	-	-	-	-	-	-	12.55	12.06	(7.11)	24.61	(6.60)	(67.30)
XXVII	Earning per share for discontinued operations (EPS)												
	(not annualised except for the year ended 31 March)												
	Basic (in Rupees)	-	-	-	-	-	-	-	-	4.21	-	9.01	14.08
	Diluted (in Rupees)	-	-	-	-	-	-	-	-	4.21	-	9.01	14.08
XXVIII	Earning per share for continuing and discontinued operations (EPS)												
	(not annualised except for the year ended 31 March)												
	Basic (in Rupees)	21.09	16.08	10.72	37.17	20.34	183.13	12.55	12.06	(2.90)	24.61	2.41	(53.22)
	Diluted (in Rupees)	21.09	16.08	10.72	37.17	20.34	183.12	12.55	12.06	(2.90)	24.61	2.41	(53.22)

Glenmark Pharmaceuticals Limited

Statement of assets and liabilities

(All amounts in million of Indian Rupees, unless otherwise stated)

Particulars	Standalone		Consolidated	
	As at 30/09/2024 Unaudited	As at 31/03/2024 Audited	As at 30/09/2024 Unaudited	As at 31/03/2024 Audited
ASSETS				
Non current assets				
Property, plant and equipment	15,625.40	14,970.05	29,755.96	29,190.77
Capital work-in-progress	1,697.54	1,754.95	3,951.14	4,193.24
Right of Use Asset	452.59	415.73	1,795.08	1,990.76
Goodwill	-	-	702.66	673.59
Other intangible assets	1,952.42	2,176.67	10,840.52	10,246.50
Intangible assets under development	344.27	221.70	1,973.64	2,425.56
Financial assets				
(i) Investments	1,51,831.64	1,29,647.91	446.11	7,896.64
(ii) Loans	37,878.02	75,056.60	-	-
(iii) Other financial assets	436.98	444.59	700.10	698.83
Deferred tax assets (net)	492.84	1,658.47	10,786.88	10,497.22
Other non-current assets	587.22	982.53	1,066.56	1,492.31
Total non-current assets	2,11,298.92	2,27,329.20	62,018.65	69,305.42
Current assets				
Inventories	12,687.68	11,426.86	28,402.06	25,130.51
Financial assets				
(i) Investments	-	-	-	-
(ii) Trade receivables	32,981.77	24,844.74	28,634.30	18,584.12
(iii) Cash and cash equivalents	9,731.48	1,279.64	18,188.96	16,582.70
(iv) Bank balance other than cash and cash equivalents	11.80	11.86	13.48	11.86
(v) Other financial assets	1,370.80	1,305.59	2,204.54	1,735.97
Current tax assets	-	-	-	-
Other current assets	7,151.74	7,946.05	12,891.43	12,235.66
Total current assets	63,935.27	46,814.74	90,334.77	74,280.82
Total assets	2,75,234.19	2,74,143.94	1,52,353.42	1,43,586.24
EQUITY AND LIABILITIES				
Equity				
Equity share capital	282.19	282.19	282.19	282.19
Other equity	2,39,174.04	2,29,424.01	84,174.39	78,197.08